Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced the appointment of Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, effective March 1, 2026. Dr. Zhang, aged 65, brings extensive experience from pharmaceutical and biotechnology companies worldwide.

Dr. Zhang previously led the medicinal chemistry section at Organon research laboratories in Glasgow from 1997 to 2001 and co-founded several biotechnology ventures before joining multinational pharmaceutical firms. Between 2003 and 2009, Dr. Zhang served as senior vice president of research & development at Biotica Technology Ltd in Cambridge, focusing on synthetic biology. He later held roles at F. Hoffmann-La Roche’s R&D Centre in China and returned to Merck Sharp & Dohme as corporate vice president and head of Asia Pacific Research & Development from 2011 to 2012. Since 2012, he had been corporate vice president of R&D and head of the Asia Research & Development Center at Amgen Inc.

According to the announcement, Dr. Zhang’s background is expected to support business development activities worldwide and guide the research and development of novel drugs. The board expressed confidence that his extensive experience and in-depth knowledge will help the company achieve new milestones and strengthen its strategic direction moving forward.